Compare INAB & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INAB | ICMB |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 10.8M |
| IPO Year | 2020 | 2013 |
| Metric | INAB | ICMB |
|---|---|---|
| Price | $0.82 | $1.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 35.4K | ★ 98.5K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | ★ 22.65% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.59 |
| 52 Week High | $2.73 | $3.12 |
| Indicator | INAB | ICMB |
|---|---|---|
| Relative Strength Index (RSI) | 34.98 | 76.69 |
| Support Level | N/A | $0.80 |
| Resistance Level | $1.50 | $1.29 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 2.00 | 87.75 |
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.